You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
Funded by a five-year, $3.7 million NIH grant, the firm plans to offer an assay that is cheaper and less invasive than standard upper endoscopies.
The nanosensors will target low-cost, handheld diagnostics and are expected to be able to detect and quantify specific molecules in biofluids in 30 seconds.
The partners are validating three rapid diagnostic test prototypes prior to initiating a trial in the Democratic Republic of the Congo during March 2020.
PerkinElmer is providing its recently FDA-approved test for the program, which has identified one baby, so far, as positive for DMD.
Genetron will provide clinical trial genomic testing and companion diagnostic development services for InnoCare's biomarker-driven oncology drug development.
The two organizations are collaborating to perform a standardized evaluation of currently available molecular diagnostic tests to assess test performance.
The project, the first under a partnership between the university and Illumina announced last year, will apply whole-genome sequencing to challenging cancers types.
The firms will collaborate to develop a blood collection device and automated sample handling and analytic technologies for use in decentralized testing.
Natera's Signatera test will be used to select and monitor eligible patients with KRAS-mutant tumors who have molecular residual disease after surgery.
The companies will use ProSciento's Nash Pass patient registry and Nordic Bioscience's biomarker technology to validate the translational biomarkers.